Nuvectis Pharma, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | 117.1% | 117.1% | -193.6% |
| FY2022 | -134.2% | -134.2% | -93.5% |
| FY2023 | -182.4% | -182.4% | -116.0% |
| FY2024 | -195.6% | -195.6% | -102.1% |
| FY2025 | -143.6% | -143.6% | -83.4% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | 117.1% | 117.1% | -193.6% |
| FY2022 | -134.2% | -134.2% | -93.5% |
| FY2023 | -182.4% | -182.4% | -116.0% |
| FY2024 | -195.6% | -195.6% | -102.1% |
| FY2025 | -143.6% | -143.6% | -83.4% |